title: Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
abstract: Osteoporosis affects more than 28 million Americans. With the advent of accessible and affordable diagnostic studies, awareness and recognition of this disease by patients and clinicians are growing. Osteoporotic fractures of the spine and hip are costly and associated with significant morbidity and mortality. Over the past decade, a surge of new antiosteoporotic drugs have been labeled or are awaiting labeling by the U.S. Food and Drug Administration. One class of agents used to treat osteoporosis is the bisphosphonates, which inhibit bone resorption, cause an increase in bone mineral density and reduce the risk of future fractures caused by aging, estrogen deficiency and corticosteroid use. Overall, bisphosphonates have been shown to have a strong safety and tolerability profile.
authors.affiliation: University of Pittsburgh School of Medicine, Pennsylvania, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Greenspan
authors.forename: S T
authors.initials: ST
authors.lastname: Harris
authors.forename: H
authors.initials: H
authors.lastname: Bone
authors.forename: P D
authors.initials: PD
authors.lastname: Miller
authors.forename: E S
authors.initials: ES
authors.lastname: Orwoll
authors.forename: N B
authors.initials: NB
authors.lastname: Watts
authors.forename: C J
authors.initials: CJ
authors.lastname: Rosen
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*
chemical_list: D004164:Diphosphonates; D019386:Alendronate